Diarrhea-predominant Irritable Bowel Syndrome

Gastroenterology
2
Pipeline Programs
3
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Astellas
AstellasChina - Shenyang
2 programs
1
YM060Phase 31 trial
RamosetronN/A1 trial
Active Trials
NCT02612649Completed793Est. Mar 2018
NCT01736423Completed151Est. May 2014
Cosmo Pharmaceuticals
Cosmo PharmaceuticalsIreland - Dublin
1 program
1
Rifamycin SV 600mg t.i.d.Phase 21 trial
Active Trials
NCT03099785CompletedEst. Dec 2020
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
GelsectanN/A1 trial
Active Trials
NCT07000383RecruitingEst. Mar 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AstellasYM060
Cosmo PharmaceuticalsRifamycin SV 600mg t.i.d.
City TherapeuticsGelsectan
AstellasRamosetron

Clinical Trials (4)

Total enrollment: 944 patients across 4 trials

NCT01736423AstellasYM060

A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome

Start: Sep 2012Est. completion: May 2014151 patients
Phase 3Completed
NCT03099785Cosmo PharmaceuticalsRifamycin SV 600mg t.i.d.

Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D

Start: Dec 2017Est. completion: Dec 2020
Phase 2Completed
NCT07000383City TherapeuticsGelsectan

Evaluation of the Efficacy and Safety of Gelsectan in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome

Start: Jun 2025Est. completion: Mar 2026
N/ARecruiting
NCT02612649AstellasRamosetron

Special Drug Use Surveillance of Irribow in Female Patients

Start: Oct 2015Est. completion: Mar 2018793 patients
N/ACompleted

Related Jobs in Gastroenterology

Specialty Representative, Gastroenterology – Minneapolis, Minnesota

AbbVie
Remote
12h ago

Head of Drug Product Development

Ironwood Pharmaceuticals
Boston, Massachusetts, United States
14h ago
$246K - $287K/yr

Regulatory Affairs Associate

Ferring Pharmaceuticals
Istanbul, Turkey
Yesterday

Key Account Director, Diagnostics and Research

Tempus
Remote
Yesterday
$150K - $200K/yr

Senior Sterilization Validation Engineer (m/f/d)

Johnson & Johnson
Beerse, Antwerp, Belgium
Yesterday

Senior Financial Analyst - Supply Chain Finance & Transformation (m/f/d)

Johnson & Johnson
Norderstedt, Schleswig-Holstein, Germany
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 944 patients
3 companies competing in this space

Related Indications

Hepatic Impairment(79)Gastroesophageal Reflux Disease(37)Irritable Bowel Syndrome(29)Gastroesophageal Reflux(27)Liver Transplantation(24)Celiac Disease(23)Hepatic Insufficiency(22)Liver Cirrhosis(22)Gastroesophageal Reflux Disease (GERD)(14)Hepatic Encephalopathy(12)